ArticleThe Lancet. Respiratory medicine2021
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial.
Article in The Lancet. Respiratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.Journal of medical virology · 2022Pooled it
- Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.The Lancet. Respiratory medicine · 2022Trial
- Rethinking MS Therapeutics: From Disease Pathogenesis Mechanisms to AI-Driven Drug Discovery.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Review
- Pattern Recognition Algorithms in Pharmacogenomics and Drug Repurposing-Case Study: Ribavirin and Lopinavir.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The future of pharmaceuticals: Artificial intelligence in drug discovery and development.Journal of pharmaceutical analysis · 2025Review
- Baricitinib statistically significantly reduced COVID-19-related mortality: a systematic review and meta-analysis of five phase III randomized, blinded and placebo-controlled clinical trials.Biology methods & protocols · 2024Review
- Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections.Open forum infectious diseases · 2023Article
- Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Article
- Growth Arrest of Alveolar Cells in Response to Cytokines from Spike S1-Activated Macrophages: Role of IFN-γ.Biomedicines · 2022Article
- Complement C5a inhibition: a new form of COVID-19 treatment for mechanically ventilated patients?The Lancet. Respiratory medicine · 2022Article
- Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.Transfusion · 2022Article
- The JAK1/2 Inhibitor Baricitinib Mitigates the Spike-Induced Inflammatory Response of Immune and Endothelial Cells In Vitro.Biomedicines · 2022Article
- Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework.Journal of clinical medicine · 2022Review
- The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19.Vaccines · 2022Review
- Computational drug repurposing in the age of COVID-19: mixing antiviral cocktails in silico.NPJ digital medicine · 2022Article
- An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).International immunopharmacology · 2022Review
- Article
- COVID-19 and antimicrobial resistance: A cross-study.The Science of the total environment · 2022Review
- Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?Drug design, development and therapy · 2022Review
- Mortality in solid organ transplant recipients hospitalized for COVID-19.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.